Denali Therapeutics director sells $261,928 in stock

Denali Therapeutics Inc. (NASDAQ:DNLI) director Nancy Thornberry sold 11,439 shares of the company's common stock on September 2, 2026, for a total of $261,928. The shares were sold under a Rule 10b5-1 trading plan, with prices ranging from $22.54 to $23.85 per share. As of the sale, DNLI stock was trading at $22.28, up 35% year-to-date and 44% over the past year, though still 18% below its 52-week high of $27.30.

Thornberry now directly holds 19,686 shares of Denali Therapeutics common stock, including 6,408 unvested Restricted Stock Units (RSUs). Despite these recent sales, the company's stock saw an increase in after-hours trading following the announcement of its first approved medicine, AVLAYAH, which generated $3.6 million in its initial full commercial quarter following FDA approval.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.